US Market Focus Leverage Sun Pharma US's strong dependence on the United States market (roughly 50% of turnover) and 93% from finished dosage forms to tailor value propositions for US-based payers, distributors, and healthcare providers.

Strategic Acquisitions Position opportunities around the recent Innovcare Lifesciences acquisition and upcoming product expansions to accelerate portfolio breadth, licensing deals, and exclusive distribution arrangements in target segments.

Pipeline Readiness Capitalise on a robust US FDA approval pipeline by offering accelerated registration support, contract manufacturing partnerships, and supply chain solutions to shorten time-to-market for generics.

Product Expansion Target Sun Pharma’s ongoing product launches (11 new products in the latest quarter; 37 in FY26) with co-promotion, territory expansion, and bundled mono-therapy and combination therapy opportunities.

Strategic Partnerships Explore partnerships around manufacturing capacity, quality compliance, and analytics with Sun Pharma’s global footprint (26 locations) to meet demand spikes in the US and other markets, while aligning with their strong manufacturing base.